AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -13.0% according to Deutsche.
Deutsche set a target price of 10,500 GBX for the company, which when compared to the AstraZeneca plc share price of 12,070 GBX at opening today (26/04/2024) indicates a potential downside of -13.0%. Trading has ranged between 9,461 (52 week low) and 12,210 (52 week high) with an average of 1,782,409 shares exchanging hands daily. The market capitalisation at the time of writing is £184,593,120,000.
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.
AstraZeneca plc -13.0% potential downside indicated by Deutsche
- Written by: Charlotte Edwards
Latest Company News
The US FDA has approved AstraZeneca and Amgen’s Tezspire (tezepelumab) as an add-on maintenance treatment for patients aged 12 and over with inadequately controlled chronic rhinosinusitis with nasal polyps.
AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients.
The European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Tezspire (tezepelumab) for adult patients with chronic rhinosinusitis with nasal polyps.
AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio.
AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all primary and secondary endpoints, with a favourable safety profile.
AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer.
